In the Phase II/III, double‐blind, randomized RELATIVITY‐047 study (NCT03470922), the researchers evaluated relatlimab (LAG‐3 blocking antibody) combined with nivolumab compared with nivolumab alone to patients with previously untreated advanced melanoma [429]. The gene discussed is LAG3; the disease is melanoma.